Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Study sponsor: Inovio Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-07-23Actual
Enrollment · participants33Actual
Source updated2023-08-25Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.